FindTrial
Sign In

During the treatment of diffuse large B cell lymphoma, the elevated LDH does not suggest a recurrence or progression of the disease

During the treatment of diffuse large B cell lymphoma, the elevated LDH does not suggest a recurrence or progression of the disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018330
Enrollment
Unknown
Registered
2018-09-12
Start date
2018-09-12
Completion date
Unknown
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B cell lymphoma

Interventions

Case series:Nil

Sponsors

Department of Hematology, the First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: DLBCL patients diagnosed in our department and receiving regular chemotherapy with CHOP or r-chop regimen;

Exclusion criteria

Exclusion criteria: (1) concomitant with other tumors; (2) in any of the following situations: those with level 2 cardiac function and above; with a poorly controlled angina;who has suffered a myocardial infarction within one year; Severe cardiac arrhythmia. (3) the combination of various hemolytic diseases; (4) abnormal renal function: Cr > 115mmol/L; (5) abnormal liver function: TBIL > 1.5 * ULN; ALT > 2.0 x ULN; AST > 2.0 x ULN; (6) muscle injury; (7) used G-csf within 1 week;

Design outcomes

Primary

MeasureTime frame
Lactate dehydrogenase isozyme;SUVmax of Heart in PET-CT;Lactate dehydrogenase;—

Secondary

MeasureTime frame
Troponin;myoglobin;creatine kinase;creatine kinase isozyme;—

Countries

China

Contacts

Public ContactLi Juan

The First Affiliated Hospital to Sun Yat-sen University

13719209240@163.com+86 13719209240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026